Pacs Group price target raised to $36 from $32 at Truist

Truist raised the firm’s price target on Pacs Group to $36 from $32 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in Healthcare Services. The sector offers “attractive core demand drivers”, ongoing M&A opportunity, and strong relative positioning, and while “ongoing selectivity” remains important, the firm remains bullish on the group’s long-term drivers – demographics, move to value-based care, and site of service redirection – underpinning its solid growth, the analyst tells investors in a research note. For the company, Truist cites its strong clinical/operating metrics, attractive opportunity to unlock value in the new/ramping cohorts, brisk ongoing M&A activity, and favorable out-year relative valuation.